他汀类药物多效药理作用及其机制研究进展

赵心彬; 倪敏; 陶霞

doi:10.3969/j.issn.1006-0111.2013.01.005

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

他汀类药物多效药理作用及其机制研究进展

赵心彬, 倪敏, 陶霞

文章导航 > 药学实践与服务 > 2013 > 31(1): 19-21

赵心彬, 倪敏, 陶霞. 他汀类药物多效药理作用及其机制研究进展[J]. 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

引用本文:

赵心彬, 倪敏, 陶霞. 他汀类药物多效药理作用及其机制研究进展[J]. 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

ZHAO Xin-bin, NI Min, TAO Xia. Progress on the multiple pharmacological activity and mechanism of statins[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

Citation:

ZHAO Xin-bin, NI Min, TAO Xia. Progress on the multiple pharmacological activity and mechanism of statins[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

他汀类药物多效药理作用及其机制研究进展

doi: 10.3969/j.issn.1006-0111.2013.01.005

第二军医大学长征医院药学部, 上海 200003

Progress on the multiple pharmacological activity and mechanism of statins

Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

摘要: 他汀类是临床上治疗高胆固醇血症主要药物, 广泛应用于冠心病一级及二级预防。近年来研究表明,他汀类药物还具有降脂外的多重作用,包括改善血管内皮功能、抗炎症、抗氧化作用、稳定动脉粥样硬化和抗肿瘤作用等。本文围绕他汀类药物对血管疾病和肿瘤的作用及机制展开综述。
- 他汀类药物 /
- 血管疾病 /
- 肿瘤
Abstract: Statins were a mainstay in the treatment of hyperlipidemia and used in the primary and secondary prevention of coronary artery disease. Recent studies indicated that there were some cholesterol-independent or pleiotropic effects of statins, including improving endothelial function, decreasing oxidative stress, inhibiting inflammation, enhancing the stability of atherosclerotic plaques and used for anticancer therapy. The effects and mechanisms of statins on vascular disease and cancer were reviewed in this paper.
- statins /
- vascular disease /
- cancer

[1]	Liao JK, Laufs U. Pleiotropic effects of stains[J]. Annu Rev Pharmacol Toxicol, 2005,45:89.
[2]	Farwell WR,D'Avolio LW,Scranton RE,et al. Stains and prostate cancer diagnosis and grade in a veterans population[J].J Natl Cancer Inst, 2011, 103(11):885.
[3]	Vaughan CJ, Gotto AM. Update on statins: 2003[J].Circulation, 2004, 110:886.
[4]	Alonso R,Mata P. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin[J].Atherosclerosis,2001, 157:423.
[5]	Tsunekawa T,Hayashi T. Cerivastain,a hydroxymethylglutaryl coenzyme reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days[J].Circulation, 2001, 104:376.
[6]	Williams JK, Sukhova GK, Herring DM, et al. Pravastain has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys[J].J Am CollCardoil, 1998, 31:684.
[7]	Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms[J].Stroke, 2004, 35:2708.
[8]	Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelim and their contribution to neovascularization by mobilization of endothelil progenitor cells[J].Coronary Artery Disease, 2004, 15:235.
[9]	陈巧玲,蔡宝祥.他汀类药物防治动脉粥样硬化作用研究进展[J].药学实践杂志,2006,24(6):321.
[10]	Assmus B, Urbich C, Aicher A, et al. HMG-CoA Reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes[J].Circulation Res, 2003, 92:1049.
[11]	Vasa M, Fichtlscherer S. Increase in circulating endotheliap progenitor cells by stain therapy in patients with stable coronary artery disease[J].Circulation, 2001, 103:2885.
[12]	Fukumoto Y, Libby P, Rabkin E, et al. Stains alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits[J].Circulation, 2001, 103:993.
[13]	Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastation, an HMG-CoA reductase inhibitor:contribution to its anti-angiogenic effect[J].FEBS Lett, 2001, 495(3):159.
[14]	Yamakawa T,Tanaka S,Kamei J,et al. Pitavsatatin inhibits vascular Smooth muscle cell proliferation by inactivating extracellular signal-regulated kinase 1/2[J].J Atheroscler Thromb,2003,10(1):37.
[15]	Richard K. The Jupiter study, CRP screening, and aggressive statin therapy implications for the primary prevention of cardiovascular disease[J].Ther Adv Cardiovasc Dis, 2009,3(4):309.
[16]	李秋荣,王勤,曲环,等.瑞舒伐他汀对血脂正常的2型糖尿病患者血清高敏C 反应蛋白的作用[J].中华高血压杂志,2011,19(3):280.
[17]	Bonetti PO, Lerman LO, et al. Stain effects beyond lipid lowering-are they clinically relevant?[J].European Heart Journal, 2003, 24(3):225.
[18]	Giannotti G,Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis[J].Herz, 2007, 32(7):568.
[19]	陈瑗,周玫.氧化应激-炎症在动脉粥样硬化发生发展中作用研究的新进展[J].中国动脉硬化杂志,2008, 16(10):757.
[20]	Hawk E, Viner JL. Statins and cancer—beyond the “one drug, one disease” model[J].N Engl J Med, 2005, 352(21):2184.
[21]	王磊,胡昌华.他汀类药物抗癌作用新机制[J].中国药学杂志,2010,45(23):1796.
[22]	Sassano A,Katsoulidis E,Antico G,et al. Suppressive effects of statins on actue promyelocytic leukemia cells[J].Cancer Res,2007, 67(9)4524.
[23]	Weis M,Heeschen C,Glassford AJ,et al. Statins have biphasic effects on angiogenesis[J].Circulation,2002, 105:739.
[24]	Fromigué O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion[J]. J Biol Chem,2008, 284(45):30549.
[25]	Cho SJ, Kim JS, Kim JM, et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts,and attenuates colitisassociated colon cancer in mice[J]. Int J Cancer, 2008, 123:951.
[26]	李颖,张增叶,姜达.洛伐他汀对恶性黑色素瘤B16细胞株的作用及其机制的研究[J]. 实用肿瘤学杂志,2008,6:520.
[27]	江庭秀,顾伟英,邱国强,等.辛伐他汀联合阿糖胞苷对K562细胞增殖与凋亡的影响[J].白血病·淋巴瘤,2011,20(1):35.
[28]	张莉.他汀类药物调脂及非调脂作用的临床新进展[J].医学信息,2011,24(7):4248.
[29]	Khurana V,Beijjanki HR,Caldito G,et al. Statins reduce the risk of lung cancer in humans,a large case-control study of US veterans[J]. Chest,2007, 131(5):1282.
[30]	吴苏舒,刘玉明,陈静.他汀类药物调脂外临床应用概况[J].药学实践杂志,2007,25(1):4.

[1]	李锐, 张倩倩, 王瑞冬, 高小峰. 国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(2): 1-6. doi: 10.12206/j.issn.2097-2024.202408031
[2]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[3]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[4]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[5]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[6]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[7]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[8]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[9]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[10]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[11]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027